Exacerbation of Cushing's syndrome during pregnancy: stimulation of a cortisol-secreting adrenocortical adenoma by ACTH originating from the foeto-placental unit.

2019 ACTH ACTH stimulation AVP Aberrant adrenal receptors Adrenal Adrenalectomy Adrenocortical adenoma Adult Antidiuretic Hormone Asian - other Back pain Canada Concentration difficulties Cortisol Cortisol (plasma) Cortisol (salivary) Cortisol, free (24-hour urine) Cushing's syndrome Dexamethasone suppression Diabetes insipidus - gestational Endocrine-related cancer Facial fullness Fatigue February Female Gestational diabetes Glucocorticoids Glucose (blood, fasting) Hypertension Hypocalcaemia Insulin Molecular genetic analysis Myasthaenia Obstetrics Peripheral oedema Prednisolone Striae Supraclavicular fat pads Ultrasound scan Unique/unexpected symptoms or presentations of a disease Weight gain

Journal

Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943

Informations de publication

Date de publication:
07 Feb 2019
Historique:
received: 16 11 2018
accepted: 16 01 2019
entrez: 10 2 2019
pubmed: 10 2 2019
medline: 10 2 2019
Statut: aheadofprint

Résumé

A 29-year-old G4A3 woman presented at 25 weeks of pregnancy with progressive signs of Cushing's syndrome (CS), gestational diabetes requiring insulin and hypertension. A 3.4 × 3.3 cm right adrenal adenoma was identified during abdominal ultrasound imaging for nephrolithiasis. Investigation revealed elevated levels of plasma cortisol, 24 h urinary free cortisol (UFC) and late-night salivary cortisol (LNSC). Serum ACTH levels were not fully suppressed (4 and 5 pmol/L (N: 2-11)). One month post-partum, CS regressed, 24-h UFC had normalised while ACTH levels were now less than 2 pmol/L; however, dexamethasone failed to suppress cortisol levels. Tests performed in vivo 6 weeks post-partum to identify aberrant hormone receptors showed no cortisol stimulation by various tests (including 300 IU hLH i.v.) except after administration of 250 µg i.v. Cosyntropin 1-24. Right adrenalectomy demonstrated an adrenocortical adenoma and atrophy of adjacent cortex. Quantitative RT-PCR analysis of the adenoma revealed the presence of ACTH (MC2) receptor mRNA, while LHCG receptor mRNA was almost undetectable. This case reveals that CS exacerbation in the context of pregnancy can result from the placental-derived ACTH stimulation of MC2 receptors on the adrenocortical adenoma. Possible contribution of other placental-derived factors such as oestrogens, CRH or CRH-like peptides cannot be ruled out. Learning points: Diagnosis of Cushing's syndrome during pregnancy is complicated by several physiological alterations in hypothalamic-pituitary-adrenal axis regulation occurring in normal pregnancy. Cushing's syndrome (CS) exacerbation during pregnancy can be associated with aberrant expression of LHCG receptor on primary adrenocortical tumour or hyperplasia in some cases, but not in this patient. Placental-derived ACTH, which is not subject to glucocorticoid negative feedback, stimulated cortisol secretion from this adrenal adenoma causing transient CS exacerbation during pregnancy. Following delivery and tumour removal, suppression of HPA axis can require several months to recover and requires glucocorticoid replacement therapy.

Identifiants

pubmed: 30738017
doi: 10.1530/EDM-18-0115
pii: EDM180115
pmc: PMC6373782
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

BJOG. 2000 Jun;107(6):810-2
pubmed: 10847243
Clin Endocrinol (Oxf). 2001 Feb;54(2):277-81
pubmed: 11207645
Ann Surg. 2001 Jul;234(1):85-91
pubmed: 11420487
Endocr Rev. 2005 Oct;26(6):775-99
pubmed: 15827110
J Endocrinol Invest. 2009 Apr;32(4):313-6
pubmed: 19636197
Endocr Pathol. 2009 Winter;20(4):256-61
pubmed: 19705299
Regul Pept. 2010 Jun 8;162(1-3):18-25
pubmed: 20171993
J Clin Endocrinol Metab. 2011 May;96(5):1533-40
pubmed: 21367926
Aust N Z J Obstet Gynaecol. 2012 Feb;52(1):96-100
pubmed: 22188308
Gynecol Endocrinol. 2013 Apr;29(4):309-10
pubmed: 23323736
Pituitary. 2016 Feb;19(1):30-8
pubmed: 26346684
Int J Cancer. 2016 Jun 15;138(12):2785-94
pubmed: 26637955
Obstet Med. 2016 Mar;9(1):43-5
pubmed: 27512490
Endocrine. 2017 Feb;55(2):555-563
pubmed: 27704478
Eur J Endocrinol. 2017 Nov;177(5):K13-K20
pubmed: 28819015
J Endocr Soc. 2017 Jan 12;1(1):57-71
pubmed: 29264446
Best Pract Res Clin Endocrinol Metab. 2018 Apr;32(2):165-187
pubmed: 29678284
Nature. 1987 Aug 20-26;328(6132):717-9
pubmed: 3039377
Obstet Gynecol. 1971 Dec;38(6):841-3
pubmed: 5125430
Obstet Gynecol. 1978 May;51(5):598-602
pubmed: 652208
Clin Endocrinol (Oxf). 1993 Sep;39(3):375-9
pubmed: 8222300
J Clin Endocrinol Metab. 1993 Aug;77(2):494-7
pubmed: 8345057
J Clin Endocrinol Metab. 1996 Jan;81(1):15-21
pubmed: 8550743
Clin Endocrinol (Oxf). 1997 May;46(5):619-26
pubmed: 9231058

Auteurs

Classifications MeSH